{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:33:25Z","timestamp":1792218805402,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CorEvitas, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10620-024-08451-4","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T17:02:01Z","timestamp":1717002121000},"page":"2784-2795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn\u2019s Disease"],"prefix":"10.1007","volume":"69","author":[{"given":"Jud C.","family":"Janak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"Loughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste A.","family":"Lemay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Korzenik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hudesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"issue":"1","key":"8451_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12960-018-0321-9","volume":"16","author":"D Allen","year":"2018","unstructured":"Allen D, Hines EW, Pazdernik V, et al. Four-year review of presenteeism data among employees of a large United States health care system: a retrospective prevalence study. Hum Resour Health. 2018;16(1):59.","journal-title":"Hum Resour Health"},{"issue":"12","key":"8451_CR2","doi-asserted-by":"publisher","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003\u20132011. PLoS One. 2012;7(12):e52935.","journal-title":"PLoS One"},{"issue":"3","key":"8451_CR3","first-page":"342","volume":"32","author":"M Kennedy","year":"2014","unstructured":"Kennedy M, Papneja A, Thavaneswaran A, et al. Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis. Clin Exp Rheumatol. 2014;32(3):342\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"8451_CR4","first-page":"199","volume":"7","author":"C Lewis-Beck","year":"2013","unstructured":"Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199\u2013205.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"8451_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40744-018-0135-1","volume":"6","author":"JF Merola","year":"2019","unstructured":"Merola JF, Shrom D, Eaton J, et al. Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey. Rheumatol Ther. 2019;6(1):33\u201345.","journal-title":"Rheumatol Ther"},{"issue":"1S Suppl 1","key":"8451_CR6","first-page":"e594-e602","volume":"33","author":"S van Gennep","year":"2021","unstructured":"van Gennep S, Gielen ME, Rietdijk ST, et al. Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e594-e602.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"8451_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjd.18798","volume":"183","author":"R Villacorta","year":"2020","unstructured":"Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548\u2013558.","journal-title":"Br J Dermatol"},{"issue":"6","key":"8451_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2165\/11310440-000000000-00000","volume":"10","author":"Y Wu","year":"2009","unstructured":"Wu Y, Mills D, Bala M. Impact of psoriasis on patients\u2019 work and productivity: a retrospective, matched case-control analysis. Am J Clin Dermatol. 2009;10(6):407\u201310.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"8451_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/MIB.0000000000000399","volume":"21","author":"A Zand","year":"2015","unstructured":"Zand A, van Deen WK, Inserra EK, et al. Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact. Inflamm Bowel Dis. 2015;21(7):1623\u201330.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"8451_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1586\/14737167.2015.965154","volume":"15","author":"P Kawalec","year":"2015","unstructured":"Kawalec P, Malinowski KP. The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):125\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"Suppl 1","key":"8451_CR11","first-page":"s34-s41","volume":"2","author":"ME Kuenzig","year":"2019","unstructured":"Kuenzig ME, Lee L, El-Matary W, et al. The impact of inflammatory bowel disease in Canada 2018: indirect costs of IBD care. J Can Assoc Gastroenterol. 2019;2(Suppl 1):s34-s41.","journal-title":"J Can Assoc Gastroenterol"},{"issue":"8","key":"8451_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/03007995.2020.1771293","volume":"36","author":"D Pilon","year":"2020","unstructured":"Pilon D, Ding Z, Muser E, et al. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Curr Med Res Opin. 2020;36(8):1285\u20131294.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"8451_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/03007995.2020.1716704","volume":"36","author":"LM Hagelund","year":"2020","unstructured":"Hagelund LM, Elkj\u00e6r Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Curr Med Res Opin. 2020;36(5):771\u2013779.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"8451_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"8451_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","volume":"12","author":"WR Best","year":"2006","unstructured":"Best WR. Predicting the Crohn\u2019s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12(4):304\u201310.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"8451_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"8451_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23\u201331.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"8451_CR18","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. Aug 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis. Aug"},{"key":"8451_CR19","doi-asserted-by":"crossref","unstructured":"Curtin LR, Klein RJ. Direct standardization (age-adjusted death rates). Healthy People 2000 Stat Notes. Mar 1995;(6):1\u201310.","DOI":"10.1037\/e584012012-001"},{"issue":"6","key":"8451_CR20","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","volume":"47","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Coates LC. Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum. 2018;47(6):786\u2013796.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"8451_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/17474124.2020.1804361","volume":"14","author":"A Dal Buono","year":"2020","unstructured":"Dal Buono A, Roda G, Argollo M, et al. Treat to target or \u2018treat to clear\u2019 in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol. 2020;14(9):807\u2013817.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"8451_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/jgh.13923","volume":"33","author":"RV Bryant","year":"2018","unstructured":"Bryant RV, Costello SP, Schoeman S, et al. Limited uptake of ulcerative colitis \u201ctreat-to-target\u201d recommendations in real-world practice. J Gastroenterol Hepatol. 2018;33(3):599\u2013607.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"8451_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb). 2021;11(1):235\u2013252.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"8451_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3899\/jrheum.161473","volume":"44","author":"DD Gladman","year":"2017","unstructured":"Gladman DD, Poulin Y, Adams K, et al. Treating psoriasis and psoriatic arthritis: position paper on applying the treat-to-target concept to Canadian daily practice. J Rheumatol. 2017;44(4):519\u2013534.","journal-title":"J Rheumatol"},{"issue":"12","key":"8451_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S2468-1253(20)30300-9","volume":"5","author":"KM Fairbrass","year":"2020","unstructured":"Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053\u20131062.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"8451_CR26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/jamapsychiatry.2020.0431","volume":"77","author":"GS Shields","year":"2020","unstructured":"Shields GS, Spahr CM, Slavich GM. Psychosocial interventions and immune system function: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2020;77(10):1031\u20131043.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"8451_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","volume":"16","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, van der Woude CJ, Ananthakrishnan AN. Fatigue in IBD: epidemiology, pathophysiology and management. Nat Rev Gastroenterol Hepatol. 2019;16(4):247\u2013259.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"8451_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/bjd.13647","volume":"172","author":"IM Skoie","year":"2015","unstructured":"Skoie IM, Ternowitz T, Jonsson G, et al. Fatigue in psoriasis: a phenomenon to be explored. Br J Dermatol. 2015;172(5):1196\u2013203.","journal-title":"Br J Dermatol"},{"issue":"9","key":"8451_CR29","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3899\/jrheum.100179","volume":"37","author":"JA Husted","year":"2010","unstructured":"Husted JA, Tom BD, Farewell VT, Gladman DD. Longitudinal analysis of fatigue in psoriatic arthritis. J Rheumatol. 2010;37(9):1878\u201384.","journal-title":"J Rheumatol"},{"issue":"5","key":"8451_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ibd.20848","volume":"15","author":"K Bielefeldt","year":"2009","unstructured":"Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(5):778\u201388.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"8451_CR31","doi-asserted-by":"publisher","first-page":"e0156666","DOI":"10.1371\/journal.pone.0156666","volume":"11","author":"J Zeitz","year":"2016","unstructured":"Zeitz J, Ak M, M\u00fcller-Mottet S, et al. Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS One. 2016;11(6):e0156666.","journal-title":"PLoS One"},{"issue":"6","key":"8451_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/apt.14493","volume":"47","author":"L Sweeney","year":"2018","unstructured":"Sweeney L, Moss-Morris R, Czuber-Dochan W, et al. Systematic review: psychosocial factors associated with pain in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47(6):715\u2013729.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"8451_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/09546634.2018.1528330","volume":"30","author":"DJ Pithadia","year":"2019","unstructured":"Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management. J Dermatolog Treat. 2019;30(5):435\u2013440.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"8451_CR34","doi-asserted-by":"publisher","first-page":"e0180014","DOI":"10.1371\/journal.pone.0180014","volume":"12","author":"S Rifbjerg-Madsen","year":"2017","unstructured":"Rifbjerg-Madsen S, Christensen AW, Christensen R, et al. Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey. PLoS One. 2017;12(7):e0180014.","journal-title":"PLoS One"},{"key":"8451_CR35","first-page":"111","volume":"8","author":"AS Bannaga","year":"2015","unstructured":"Bannaga AS, Selinger CP. Inflammatory bowel disease and anxiety: links, risks, and challenges faced. Clin Exp Gastroenterol. 2015;8:111\u20137.","journal-title":"Clin Exp Gastroenterol"},{"issue":"7","key":"8451_CR36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ibd.20873","volume":"15","author":"LA Graff","year":"2009","unstructured":"Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009;15(7):1105\u201318.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"8451_CR37","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","volume":"22","author":"A Mikocka-Walus","year":"2016","unstructured":"Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(3):752\u201362.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"8451_CR38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/jdv.13891","volume":"31","author":"P Fleming","year":"2017","unstructured":"Fleming P, Bai JW, Pratt M, et al. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31(5):798\u2013807.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"8451_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(3):351\u2013360.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"8451_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.191117","volume":"48","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Liu M, Rebello S, et al. Disease characteristics, quality of life, and work productivity by enthesitis site: real-world data from the US Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2021;48(3):367\u2013375.","journal-title":"J Rheumatol"},{"issue":"3","key":"8451_CR41","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.","journal-title":"Dermatol Ther"},{"issue":"7","key":"8451_CR42","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.crohns.2013.11.019","volume":"8","author":"ME van der Valk","year":"2014","unstructured":"van der Valk ME, Mangen MJ, Leenders M, et al. Risk factors of work disability in patients with inflammatory bowel disease\u2013a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. J Crohns Colitis. 2014;8(7):590\u20137.","journal-title":"J Crohns Colitis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08451-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:00:22Z","timestamp":1724432422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08451-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8451"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08451-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed following Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (NEIRB; no. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to CorEvitas, LLC prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Jud C. Janak accepts full responsibility for the conduct of the study and has access to the data and control of the decision to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor of the article"}},{"value":"JCJ, CAL, AML: Former Employee of CorEvitas, LLC; PCM: Employee of CorEvitas, LLC; PJM: (Grant Research) AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Inc., Sun, UCB; (Consulting) AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Inc., Sun Pharma, and UCB; (Speakers Bureau) AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Inc., and UCB; ML: Employee of Mount Sinai and receives research funds from: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc., and is a consultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Brickell Biotech, Boehringer-Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, CorEvitas, Dermavant Sciences, Dr. Reddy\u2019s Laboratories, Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica; JRK: Research Support: AbbVie, Pfizer, Inc.; Consultant: Genentech, Thetis; Founder: ColonaryConcepts; RKC: Consulting and\/or Participation in Advisory Boards for AbbVie, Bristol Myers Squibb, Eli Lilly, Fzata, LabCorp, Magellan Health, Janssen, Pfizer, Samsung Bioepis, Takeda; DH: Consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Inc., Takeda, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}